Physician profile
Wendell R Helveston
NPI 1881607158
$883,253.74
in general payments reported to CMS, 2019-2025
68 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $108K · 2021: $128K · 2022: $99K · 2023: $91K · 2024: $187K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $159K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $149K · Honoraria: $49K · Consulting Fee: $43K · Travel and Lodging: $30K · Food and Beverage: $22K · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $158,908.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $149,187.50 |
| Honoraria | $48,587.50 |
| Consulting Fee | $42,758.78 |
| Travel and Lodging | $29,719.21 |
| Food and Beverage | $21,867.81 |
| Education | $180.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $207,025.50 | 2019-2025 | |
| Abbvie INC. | $128,571.78 | 2019-2025 | |
| Biogen, INC. | $81,560.03 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Amgen INC. | $69,048.96 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $64,721.87 | 2022-2025 | Epidiolex |
| Sk Life Science, INC. | $62,393.33 | 2020-2025 | Xcopri |
| Lundbeck LLC | $60,572.76 | 2019-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $43,402.78 | 2020-2021 | |
| Allergan, INC. | $40,287.47 | 2019-2021 | |
| Ucb, INC. | $27,705.32 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Genentech USA, INC. | $24,682.62 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Impel Pharmaceuticals INC. | $16,613.55 | 2022-2023 | Trudhesa |
| Greenwich Biosciences, INC. | $15,584.14 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11,370.83 | 2022 | |
| Pfizer INC. | $5,908.95 | 2019-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $2,829.53 | 2021-2025 | |
| Argenx US, INC. | $2,792.62 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $2,679.54 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $1,349.45 | 2019-2025 | Nuplazid, Daybue |
| Genentech, INC. | $1,291.17 | 2021-2024 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $1,176.02 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,168.09 | 2019-2025 | |
| Emd Serono, INC. | $1,151.59 | 2019-2025 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $858.22 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $784.86 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Amneal Pharmaceuticals LLC | $773.73 | 2019-2025 | Ongentys, Rytary |
| Alexion Pharmaceuticals, INC. | $763.63 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $748.66 | 2021-2024 | Gocovri, Xadago, Apokyn |
| Acorda Therapeutics, INC | $445.68 | 2019-2024 | Inbrija |
| Genzyme Corporation | $425.28 | 2019-2023 | |
| Csl Behring | $331.90 | 2019-2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $305.58 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $303.05 | 2023-2025 | Rexulti, Nuedexta |
| Catalyst Pharmaceuticals, INC. | $288.42 | 2023-2025 | Fycompa |
| Livanova USA, INC. | $250.00 | 2019 | |
| Kyowa Kirin, INC. | $197.06 | 2020-2024 | Nourianz |
| Abbott Laboratories | $193.36 | 2025 | Infinity |
| Grifols USA, LLC | $190.85 | 2019-2024 | Gamunex-C |
| Ge Healthcare | $189.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $172.55 | 2021-2023 | Ponvory |
| Sumitomo Pharma America, INC. | $170.58 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $164.51 | 2025 | Symbravo |
| Adamas Pharmaceuticals, INC. | $152.35 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $138.97 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Tanabe Pharma America, INC. | $123.45 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $121.67 | 2019-2021 | |
| Daiichi Sankyo INC. | $116.74 | 2019 | |
| Zogenix INC. | $112.45 | 2021 | |
| Octapharma USA, INC. | $111.29 | 2022-2025 | Panzyga |
| Neurelis, INC. | $105.71 | 2022-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $104.16 | 2019-2025 | Amvuttra |
| Mallinckrodt Hospital Products INC. | $96.72 | 2025 | Acthar |
| Avanir Pharmaceuticals, INC. | $92.42 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $83.93 | 2019-2022 | |
| Horizon Therapeutics Plc | $78.80 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $60.52 | 2024 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $55.05 | 2025 | Hyqvia |
| Mallinckrodt Enterprises LLC | $43.79 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $31.70 | 2021-2022 | |
| Medtronic, INC. | $31.17 | 2022-2024 | Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $28.62 | 2020 | |
| Amylyx Pharmaceuticals, INC. | $25.93 | 2023 | Relyvrio |
| Promius Pharma LLC | $22.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.67 | 2019 | |
| Akcea Therapeutics, INC. | $17.28 | 2020 | |
| Collegium Pharmaceutical, INC. | $17.26 | 2022 | |
| Assertio Therapeutics, INC. | $12.06 | 2020 | |
| Life Molecular Imaging Ltd | $5.23 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$940.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Helveston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.